Abstract
Background:
Kidney transplantation is the gold standard of therapy in patients with terminal renal insufficiency. Living donor transplantation is a well-established option in this field. Enlarging the donor's pool implicates the acceptance of an increased rate of comorbidities. Among them, coronary artery disease is a growing problem. An increasing number of patients, undergoing living donation, receive antiplatelet therapies due to coronary disease.
Case presentation:
Here we report about the perioperative treatment with a drug-eluting balloon in a patient with major cardiac risk factors who underwent kidney transplantation.
Conclusion:
At the current time no recommendation can be given for the routine use of drug-eluting balloons.
MeSH terms
-
Aged
-
Angioplasty, Balloon, Coronary / adverse effects
-
Angioplasty, Balloon, Coronary / instrumentation*
-
Anticoagulants / administration & dosage
-
Coronary Angiography
-
Coronary Artery Disease / diagnosis
-
Coronary Artery Disease / therapy*
-
Coronary Restenosis / diagnosis
-
Coronary Restenosis / etiology
-
Coronary Restenosis / therapy*
-
Coronary Thrombosis / etiology
-
Coronary Thrombosis / therapy
-
Diabetic Nephropathies / diagnosis
-
Diabetic Nephropathies / surgery*
-
Drug-Eluting Stents*
-
Humans
-
Kidney Transplantation / methods*
-
Living Donors*
-
Male
-
Patient Care Team
-
Percutaneous Coronary Intervention / adverse effects
-
Percutaneous Coronary Intervention / instrumentation*
-
Platelet Aggregation Inhibitors / administration & dosage
-
Prosthesis Design
-
Risk Factors
-
Time Factors
-
Treatment Outcome
Substances
-
Anticoagulants
-
Platelet Aggregation Inhibitors